XH-S003-II-101NCT06978699
A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
StatusCompleted
PhasePhase 2
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Sponsor changed: S-INFINITY Pharmaceuticals Co., Ltd to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Show 8 more changesShow less
- Eligibility criteria expanded, about 666 words
- Trial completed
- Primary completion date changed from estimate of Aug 30, 2025 to Jan 21, 2026
- Interventions modified
- Enrollment target: estimated 24 to confirmed 26
- Start date: Apr 30, 2025 to May 21, 2025
- Secondary endpoints: 5 to 7
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Changes of hemoglobin compared with baseline
Timeframe: 12 weeks from baseline
Secondary (7)
Proportion of participants with an increase in Hb ≥20g/L compared with baseline (without RBC transfusion);
Changes in Indirect Bilirubin compared to baseline;
Changes in reticulocyte counts compared to baseline;
Proportion of participants with Hb ≥120g/L (without RBC transfusion);
Changes in LDH compared with baseline
Show 2 moreShow less
Proportion of participants with LDH ≤1.5 ULN
Proportion of participants without RBC transfusion
Arms and interventions
High DoseExperimental
XH-S003 Capsule, Administered orally once daily, 125mg, 12-week continuous dosing period.
Medium DoseExperimental
XH-S003 Capsule, Administered orally once daily, 100mg, 12-week continuous dosing period.
Low DoseExperimental
XH-S003 Capsule, Administered orally once daily,50mg, 12-week continuous dosing period.
Drugs: XH-S003 Capsule
Sites
1 site in 1 country
- TianJin Medical University General HospitalTianjin, China